Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats

Erika Hanada, Hisakazu Ohtani, Hajime Kotaki, Yasufumi Sawada, Hitoshi Sato, Tatsuji Iga

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Disopyramide (DP) is known to induce QT prolongation and Torsades de Pointes (TdP) when administered concomitantly with erythromycin (EM). To define and evaluate quantitatively the arrhythmogenic risk of the concomitant administration of DP and EM, we investigated the influence of EM on the pharmacokinetics and pharmacodynamics of DP in rats. The time profiles of change in QT interval and plasma concentration of each drug were evaluated during and after constant intravenous infusion of DP (6.0 or 15.0 mg/kg/h), EM (4.0 or 8.0 mg/kg/h), and coadministration of DP and EM (DP 6.0 mg/kg/h plus EM 4.0 mg/kg/h). Each agent induced QT prolongation at plasma concentrations within the therapeutic range in humans. DP-induced QT prolongation was proportional to its plasma concentration. In the case of EM, the E(max) model with an 'effect compartment' could explain the relationship between plasma EM concentrations and changes in QT interval. Although coadministration of EM with DP gave enhanced QT prolongation compared to dosing with DP alone, EM did not affect the pharmacokinetics of DP. In conclusion, it was shown that a pharmacodynamic interaction contributes to the electrocardiographic adverse reaction (i.e., QT prolongation)induced by coadministration of DP and EM in rats.

Original languageEnglish
Pages (from-to)234-240
Number of pages7
JournalJournal of Pharmaceutical Sciences
Volume88
Issue number2
DOIs
Publication statusPublished - 1999 Feb
Externally publishedYes

Fingerprint

Pharmacodynamics
Disopyramide
Erythromycin
Rats
Plasmas
Pharmacokinetics
Torsades de Pointes
Intravenous Infusions

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Chemistry(all)
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science

Cite this

Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats. / Hanada, Erika; Ohtani, Hisakazu; Kotaki, Hajime; Sawada, Yasufumi; Sato, Hitoshi; Iga, Tatsuji.

In: Journal of Pharmaceutical Sciences, Vol. 88, No. 2, 02.1999, p. 234-240.

Research output: Contribution to journalArticle

Hanada, Erika ; Ohtani, Hisakazu ; Kotaki, Hajime ; Sawada, Yasufumi ; Sato, Hitoshi ; Iga, Tatsuji. / Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats. In: Journal of Pharmaceutical Sciences. 1999 ; Vol. 88, No. 2. pp. 234-240.
@article{013d11b58ace45d48ba20673112a40e8,
title = "Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats",
abstract = "Disopyramide (DP) is known to induce QT prolongation and Torsades de Pointes (TdP) when administered concomitantly with erythromycin (EM). To define and evaluate quantitatively the arrhythmogenic risk of the concomitant administration of DP and EM, we investigated the influence of EM on the pharmacokinetics and pharmacodynamics of DP in rats. The time profiles of change in QT interval and plasma concentration of each drug were evaluated during and after constant intravenous infusion of DP (6.0 or 15.0 mg/kg/h), EM (4.0 or 8.0 mg/kg/h), and coadministration of DP and EM (DP 6.0 mg/kg/h plus EM 4.0 mg/kg/h). Each agent induced QT prolongation at plasma concentrations within the therapeutic range in humans. DP-induced QT prolongation was proportional to its plasma concentration. In the case of EM, the E(max) model with an 'effect compartment' could explain the relationship between plasma EM concentrations and changes in QT interval. Although coadministration of EM with DP gave enhanced QT prolongation compared to dosing with DP alone, EM did not affect the pharmacokinetics of DP. In conclusion, it was shown that a pharmacodynamic interaction contributes to the electrocardiographic adverse reaction (i.e., QT prolongation)induced by coadministration of DP and EM in rats.",
author = "Erika Hanada and Hisakazu Ohtani and Hajime Kotaki and Yasufumi Sawada and Hitoshi Sato and Tatsuji Iga",
year = "1999",
month = "2",
doi = "10.1021/js980256r",
language = "English",
volume = "88",
pages = "234--240",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats

AU - Hanada, Erika

AU - Ohtani, Hisakazu

AU - Kotaki, Hajime

AU - Sawada, Yasufumi

AU - Sato, Hitoshi

AU - Iga, Tatsuji

PY - 1999/2

Y1 - 1999/2

N2 - Disopyramide (DP) is known to induce QT prolongation and Torsades de Pointes (TdP) when administered concomitantly with erythromycin (EM). To define and evaluate quantitatively the arrhythmogenic risk of the concomitant administration of DP and EM, we investigated the influence of EM on the pharmacokinetics and pharmacodynamics of DP in rats. The time profiles of change in QT interval and plasma concentration of each drug were evaluated during and after constant intravenous infusion of DP (6.0 or 15.0 mg/kg/h), EM (4.0 or 8.0 mg/kg/h), and coadministration of DP and EM (DP 6.0 mg/kg/h plus EM 4.0 mg/kg/h). Each agent induced QT prolongation at plasma concentrations within the therapeutic range in humans. DP-induced QT prolongation was proportional to its plasma concentration. In the case of EM, the E(max) model with an 'effect compartment' could explain the relationship between plasma EM concentrations and changes in QT interval. Although coadministration of EM with DP gave enhanced QT prolongation compared to dosing with DP alone, EM did not affect the pharmacokinetics of DP. In conclusion, it was shown that a pharmacodynamic interaction contributes to the electrocardiographic adverse reaction (i.e., QT prolongation)induced by coadministration of DP and EM in rats.

AB - Disopyramide (DP) is known to induce QT prolongation and Torsades de Pointes (TdP) when administered concomitantly with erythromycin (EM). To define and evaluate quantitatively the arrhythmogenic risk of the concomitant administration of DP and EM, we investigated the influence of EM on the pharmacokinetics and pharmacodynamics of DP in rats. The time profiles of change in QT interval and plasma concentration of each drug were evaluated during and after constant intravenous infusion of DP (6.0 or 15.0 mg/kg/h), EM (4.0 or 8.0 mg/kg/h), and coadministration of DP and EM (DP 6.0 mg/kg/h plus EM 4.0 mg/kg/h). Each agent induced QT prolongation at plasma concentrations within the therapeutic range in humans. DP-induced QT prolongation was proportional to its plasma concentration. In the case of EM, the E(max) model with an 'effect compartment' could explain the relationship between plasma EM concentrations and changes in QT interval. Although coadministration of EM with DP gave enhanced QT prolongation compared to dosing with DP alone, EM did not affect the pharmacokinetics of DP. In conclusion, it was shown that a pharmacodynamic interaction contributes to the electrocardiographic adverse reaction (i.e., QT prolongation)induced by coadministration of DP and EM in rats.

UR - http://www.scopus.com/inward/record.url?scp=0032970827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032970827&partnerID=8YFLogxK

U2 - 10.1021/js980256r

DO - 10.1021/js980256r

M3 - Article

VL - 88

SP - 234

EP - 240

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 2

ER -